News & Updates

Mirvetuximab soravtansine (MIRV), an antibody drug conjugate (ADC), showed antitumour activity in women with platinum-resistant ovarian cancer* (PROC) with high folate receptor alpha (FRα) expression, findings from the phase III SORAYA study have shown.

Pathological response at cystectomy may improve with maximal resection in patients undergoing transurethral resection for muscle-invasive bladder cancer prior to neoadjuvant chemotherapy, according to a study.

In the pivotal phase III ZIRCON study, PET/CT imaging with ⁸⁹Zr-DFO-girentuximab, an investigational imaging agent, demonstrated potential in the noninvasive identification of clear-cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IDRM).

Adding dostarlimab or pembrolizumab to standard first-line (1L) chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, two phase III trials have shown.

Eating nuts may not be beneficial in terms of reducing the risk of total, advanced, nonadvanced, and fatal prostate cancer, according to the results of a meta-analysis.

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, improves progression-free survival (PFS) and responses vs standard regimens in patients with triple class–exposed relapsed and refractory multiple myeloma (R/R MM), the phase III KarMMa-3 trial has shown.